Indian pharma will need to explore niche area of orphan drugs for rare diseases, often incentivized by global regulatory authorities. In fact, it will be prudent for them to invest in mRNA technology, ...

The pre-budget document tabled in Parliament on Friday said that the government must focus on a multi-pronged approach with stricter FSSAI labelling norms, higher GST, and awareness campaigns to curb ...